Compare Alliant Energy Corporation (LNT) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alliant Energy Corporation vs Sanofi SA — how do they compare? Alliant Energy Corporation trades at $70.21 (market cap $17.78B), while Sanofi SA trades at $43.6 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 5.9× Alliant Energy Corporation's market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| LNT | SNY | |
|---|---|---|
Market Cap | $17.78B | $104.30B |
Sector | Utilities | Health |
52-Week High | $78.03 | $52.34 |
52-Week Low | $63.62 | $41.33 |
Enterprise Value | $29.88B | $124.19B |
Dividend Yield | 3.12% | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alliant Energy (LNT) trades at $70.01, up 2.64% today. The stock shows a bearish technical trend with support at $67-$68 and resistance at $69-$70. Fundamentally, the company reported strong Q2 2026 earnings of $0.65 per share, beating estimates, and maintains solid profitability with an 18.45% net income margin. Analyst consensus is a 'Buy' with a $77.67 price target, implying 11% upside. Recent news highlights institutional buying and dividend stability.
LNT offers a stable investment with consistent earnings growth and a reliable dividend, but faces risks from rising debt levels and regulatory pressures. The stock's current valuation at a P/E of 21.7 is reasonable for a utility, supporting a cautious bullish outlook amid technical weakness.
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
